Next Article in Journal
Human-Based Immune Responsive In Vitro Infection Models for Validation of Novel TLR4 Antagonists Identified by Computational Discovery
Previous Article in Journal
Torque Teno Sus Virus (TTSuV) Prevalence in Wild Fauna of Northern Italy
Previous Article in Special Issue
Toxocara canis- and Toxocara cati-Induced Neurotoxocarosis Is Associated with Comprehensive Brain Transcriptomic Alterations
Article

Therapy and Prevention for Human Toxocariasis

1
Service de Parasitologie Médicale, Faculté de Médecine, Université de Toulouse, 37 Allées Jules-Guesde, 31000 Toulouse, France
2
Service de Parasitologie, Ecole Nationale Vétérinaire, 23 Chemin des Capelles, 31076 Toulouse, France
3
Service de Parasitologie-Mycologie, Hôpital Purpan, Centre Hospitalier Universitaire de Toulouse, 330 Avenue de Grande-Bretagne, 31059 Toulouse, France
*
Author to whom correspondence should be addressed.
Academic Editor: Graham H. Mitchell
Microorganisms 2022, 10(2), 241; https://doi.org/10.3390/microorganisms10020241
Received: 17 December 2021 / Revised: 17 January 2022 / Accepted: 18 January 2022 / Published: 22 January 2022
For the last four decades, knowledge about human toxocariasis with regard to its epidemiology, pathophysiology, clinical spectrum, and imaging or laboratory diagnosis has substantially progressed. Knowledge about specific therapy with anthelmintics has lagged behind. To date, only four drugs are registered for human use, and their efficacy has rarely been assessed in prospective controlled trials. It is likely that the repurposing of potent anthelmintics from veterinary medicine will improve this situation. Due to its wide availability and a lack of major side effects during short regimens, albendazole has become the drug of choice. However, its efficacy should be more precisely assessed. The role of anthelmintics in the treatment of neurological or ocular toxocariasis remains to be clarified. Prophylactic measures in humans or companion animals are efficient and represent first-line treatments for the control of this zoonosis. Unfortunately, their implementation in areas or countries where toxocariasis epidemiology is driven by poverty is quite difficult or unrealistic. View Full-Text
Keywords: toxocariasis; treatment; benzimidazoles; albendazole; mebendazole; thiabendazole; diethylcarbamazine; prevention; emodepside toxocariasis; treatment; benzimidazoles; albendazole; mebendazole; thiabendazole; diethylcarbamazine; prevention; emodepside
MDPI and ACS Style

Magnaval, J.-F.; Bouhsira, E.; Fillaux, J. Therapy and Prevention for Human Toxocariasis. Microorganisms 2022, 10, 241. https://doi.org/10.3390/microorganisms10020241

AMA Style

Magnaval J-F, Bouhsira E, Fillaux J. Therapy and Prevention for Human Toxocariasis. Microorganisms. 2022; 10(2):241. https://doi.org/10.3390/microorganisms10020241

Chicago/Turabian Style

Magnaval, Jean-François, Emilie Bouhsira, and Judith Fillaux. 2022. "Therapy and Prevention for Human Toxocariasis" Microorganisms 10, no. 2: 241. https://doi.org/10.3390/microorganisms10020241

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop